charging a co-payment for Diabetic Retinopathy screening
OtherThe intervention is charging a co-payment of HK$60 for the Diabetic Retinopathy screening.
NCT Number: NCT01628289
Introduction: There is no debate that people with diabetes should be screened for the development of retinopathy which can threaten their sight. However, there is no routine screening for retinopathy in Hong Kong at present. Many overseas countries find that they miss a large proportion of their target population and, with reliance on co-payments for screening, as is the case with the limited opportunistic screening at present, the cost-effectiveness of any routine service in Hong Kong could be reduced as is predicted by Hart's inverse care law.
Aim: This study will determine the potential cost-effectiveness of screening for retinopathy in Hong Kong under a free system and one in which a co-payment is charged.
Methods: Primary care patients attending General Outpatient Clinics on Hong Kong Island for their routine diabetic care will randomly be offered screening either at no charge or with the normal co-payment of $65. Those who are willing and unwilling to be screened will be compared for their clinical, lifestyle and socioeconomic characteristics and those unwilling will be asked their reasons. The uptake of screening at no fee and with a payment will be compared as will the prevalence of retinopathy in the two fee groups. Subsequent screening at one year will be offered at the same fee and uptake again compared.
The principal analyses will (a) identify the characteristics of those willing to be screened and reasons for not being screened (b) the uptake of screening when a co-payment is charged compared to when it is free (c) whether there is a difference in the prevalence of retinopathy between the group willing to pay and those who accept free screening and (d) the uptake of re-screening in year 2.
The resulting cost-effectiveness model will use these data, the cost data collected during the study and overseas data on benefits of treatment to model the cost-effectiveness of screening for retinopathy in Hong Kong if it were to be offered free or with a co-payment. This information will be important to determine the most cost-effective means of implementing this preventative strategy to preserve sight and quality of life.
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
Aberdeen General Outpatient Clinic,Hospital Authority, Hong Kong, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The intervention is charging a co-payment of HK$60 for the Diabetic Retinopathy screening.
The intervention is to provide free screening without charging a co-payment
Time frame: the first year
The extent of diabetic retinopathy in two groups were measured in the first year screening.
Time frame: the first year
Whether the subject attends the screening was measured and the attendance rate was estimated for two groups in the first year screening.
Time frame: the second year
The extent of diabetic retinopathy in two groups were measured in the second year screening.
Time frame: the second year
Whether the subject attends the screening was measured and the attendance rate was estimated for two groups in the second year screening.
The University of Hong Kong
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07707856
Cardiovascular Diseases, Diabetes Complications
Banhā, Benha, Egypt
View Trial DetailsNCT04132401
Age-Related Macular Degeneration, Cardiovascular Diseases
Manresa, Barcelona, Spain
View Trial DetailsNCT04505566
Cardiovascular Diseases, Diabetes Complications
Nashville, Tennessee, United States
View Trial DetailsNCT07255326
Autoimmune Diseases, Cardiovascular Diseases
Faisalabad, Punjab Province, Pakistan
View Trial Details